4//SEC Filing
Driscoll Martin J 4
Accession 0001209191-20-017232
CIK 0001566373other
Filed
Mar 8, 8:00 PM ET
Accepted
Mar 9, 4:10 PM ET
Size
8.0 KB
Accession
0001209191-20-017232
Insider Transaction Report
Form 4
Driscoll Martin J
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2020-03-05+40,000→ 40,000 totalExercise: $1.41Exp: 2030-03-04→ Common Stock (40,000 underlying) - Award
Restricted Stock Units
2020-03-05+40,000→ 40,000 total→ Common Stock (40,000 underlying)
Footnotes (3)
- [F1]This option was granted on March 5, 2020, with 25% of the shares subject to the option vesting on March 5, 2021 and the remaining 75% of the shares subject to the option vesting in 36 equal monthly installments thereafter.
- [F2]Each restricted stock unit represents a contingent right to receive one share of Spring Bank Pharmaceuticals, Inc. common stock.
- [F3]The restricted stock units will vest in two installments. Fifty percent will vest on March 5, 2021 and the remaining fifty percent will vest on December 31, 2021.
Documents
Issuer
Spring Bank Pharmaceuticals, Inc.
CIK 0001566373
Entity typeother
Related Parties
1- filerCIK 0001339402
Filing Metadata
- Form type
- 4
- Filed
- Mar 8, 8:00 PM ET
- Accepted
- Mar 9, 4:10 PM ET
- Size
- 8.0 KB